Role of oral amiodarone in patients with atrial fibrillation and congestive heart failure

Journal of Cardiology

Volumn 58, Issue 2, 2011, Pages 108-115

  Kawabata, Mihoko ^a   Hirao, Kenzo ^a   Hachiya, Hitoshi ^a   Higuchi, Kouji ^a   Tanaka, Yasuaki ^a   Yagishita, Atsuhiko ^a   Inaba, Osamu ^a   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Amiodarone; Atrial fibrillation; B type natriuretic peptide; Heart failure

Indexed keywords

AMIODARONE; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; BRADYCARDIA; CARDIOVERSION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE SIZE; HOLTER MONITORING; HUMAN; HYPOTHYROIDISM; LIVER DYSFUNCTION; LUNG INJURY; MALE; QT PROLONGATION; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SICK SINUS SYNDROME; SINUS BRADYCARDIA; SINUS RHYTHM; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RETROSPECTIVE STUDIES; STROKE VOLUME; TREATMENT OUTCOME;

EID: 80052037224     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.06.005     Document Type: Article

References (27)

1. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation Atrial fibrillation: current understanding and research imperatives. J Am Coll Cardiol 1993, 22:1830-1834.
2. Waldo A.L. Management of atrial fibrillation: the need for AFFIRMative action. Am J Cardiol 1999, 84:698-700.
3. Camm A.J., Kirchhof P., Lip G.Y., Schotten U., Savelieva I., Ernst S., Van Gelder I.C., Al-Attar N., Hindricks G., Prendergast B., Heidbuchel H., Alfieri O., Angelini A., Atar D., Colonna P., et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace 2010, 12:1360-1420.
4. Kerin N.Z., Faitel K., Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs. quinidine for conversion of atrial fibrillation. Arch Intern Med 1996, 156:49-53.
5. Gosselink A.T., Crijns H.J., van Gelder I.C., Hillige H., Wiesfeld A.C., Lie K.I. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992, 267:3289-3293.
6. Channer K.S., Birchall A., Steeds R.P., Walters S.J., Yeo W.W., West J.N., Muthusamy R., Rhoden W.E., Saeed B.T., Batin P., Brooksby W.P., Wilson I., Grant S. A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J 2004, 25:144-150.
7. Capucci A., Villani G.Q., Aschieri D., Rosi A., Piepoli M.F. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 2000, 21:66-73.
8. Galperin J., Elizari M.V., Chiale P.A., Molina R.T., Ledesma R., Scapín A.O., Vázquez Blanco M., GEFCA Investigators GEMA Group Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. J Cardiovasc Pharmacol Ther 2001, 6:341-350.
9. Manios E.G., Mavrakis H.E., Kanoupakis E.M., Kallergis E.M., Dermitzaki D.N., Kambouraki D.C., Vardas P.E. Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study. Cardiovasc Drugs Ther 2003, 17:31-39.
10. Singh B.N., Singh S.N., Reda D.J., Tang X.C., Lopez B., Harris C.L., Fletcher R.D., Sharma S.C., Atwood J.E., Jacobson A.K., Lewis H.D.JJr, Raisch D.W., Ezekowitz M.D. Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005, 352:1861-1872.
11. Mostow N.D., Vrobel T.R., Noon D., Rakita L. Rapid control of refractory atrial tacharrhythmia with high-dose oral amiodarone. Am Heart J 1990, 120:1356-1363.
12. Hohnloser S.H., Kuck K-H., Lilienthal J., for the PIAF Investigators Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000, 356:1789-1794.
13. Tieleman R.G., Gosselink A.T., Crijns H.J., van Gelder I.C., van den Berg M.P., de Kam P.J., van Gilst W.H., Lie K.I. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997, 79:53-57.
14. Kochiadakis G.E., Igoumenidis N.E., Parthenakis F.I., Chlouverakis G.I., Vardas P.E. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1999, 33:966-971.
15. Zehender M., Hohnloser S., Muller B., Meinertz T., Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992, 19:1054-1059.
16. Khand A.U., Rankin A.C., Kaye G.C., Cleland J.G. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J 2000, 21:614-632.
17. Deedwania P.C., Singh B.N., Ellenbogen K., Fisher S., Fletcher R., Singh S.N., The Department of Veterans Affairs CHF-STAT Investigators Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation 1998, 98:2574-2579.
18. Shiga T., Wakaumi M., Imai T., Suzuki T., Hosaka F., Yamada Y., Matsuda N., Shoda M., Sugiura R., Hagiwara N., Kasanuki H. Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. Circ J 2002, 66:600-604.
19. Singh B.N. Controlling cardiac arrhythmias: an overview with a historical perspective. Am J Cardiol 1997, 80:4G-15G.
20. Wyse D.G., Waldo A.L., DiMarco J.P., Domanski M.J., Rosenberg Y., Schron E.B., Kellen J.C., Greene H.L., Mickel M.C., Dalquist J.E., Corley S.D. Atrial fibrillation follow-up. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
21. Roy D., Talajic M., Nattel S., Wyse D.G., Dorian P., Lee K.L., Bourassa M.G., Arnold J.M., Buxton A.E., Camm A.J., Connolly S.J., Dubuc M., Ducharme A., Guerra P.G., Hohnloser S.H., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008, 358:2667-2677.
22. Dorian P., Mangat I. Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation. Card Electrophysiol Rev 2003, 7:276-279.
23. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., Arensberg D., Baker A., Friedman L., Greene H.L., Huther M.L., Richardson D.W., The CAST Investigators Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the cardiac arrhythmia suppression trial. N Engl J Med 1991, 324:781-788.
24. SWORD Investigators, Waldo A.L., Camm A.J., deRuyter H. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after myocardial infarction. Lancet 1996, 348:7-12.
25. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., Strömberg A., van Veldhuisen D.J., Atar D., Hoes A.W., Keren A., Mebazaa A., Nieminen M., Priori S.G., Swedberg K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 10:933-989.
26. Baba O., Izuhara M., Kadota S., Mitsuoka H., Shioji K., Uegaito T., Mutsuo S., Matsuda M. Determinant factors of plasma B-type natriuretic peptide levels in patients with persistent nonvalvular atrial fibrillation and preserved left ventricular systolic function. J Cardiol 2009, 54:402-408.
27. Kimura M., Ogawa H., Wakeyama T., Takaki A., Iwami T., Hadano Y., Mochizuki M., Hiratsuka A., Shimizu A., Matsuzaki M. Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure. J Cardiol 2011, 57:208-214.